A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers
Status:
Active, not recruiting
Trial end date:
2022-01-06
Target enrollment:
Participant gender:
Summary
Phase I/Ib multicenter clinical trial. Single agent dose escalation of NIZ985 followed by
expansion. Second escalation of NIZ985 in combination with PDR001 followed by expansion